Inovio Pharmaceuticals (INO) Analyst & Key Data

Analyst Consensus

Buy3 analysts

Buy

Updated Sep 12, 2026

Total Analysts3

Buy

10

Hold

5

Sell

2

Ratings

Updated Sep 12, 2026

Overall Rating

C-

DCF Score4.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$1.25

Median Target+206.40%

$3.83

Potential upside vs current price

DCF Value-44.63%

$0.69

Potential downside vs current price

Current Stock Price

$1.25

Median Target+206.40%

$3.83

Potential upside vs current price

DCF Value-44.63%

$0.69

Potential downside vs current price

Analyst Consensus

Buy3 analysts

Buy

Updated Sep 12, 2026

Total Analysts3

Buy

10

Hold

5

Sell

2

Ratings

Updated Sep 12, 2026

Overall Rating

C-

DCF Score4.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$1.25

Median Target+206.40%

$3.83

Potential upside vs current price

DCF Value-44.63%

$0.69

Potential downside vs current price

Current Stock Price

$1.25

Median Target+206.40%

$3.83

Potential upside vs current price

DCF Value-44.63%

$0.69

Potential downside vs current price

Inovio Pharmaceuticals, Inc.